Abstract: Described is a low voltage, pulsed electrical stimulation device for upregulating expression of klotho, a useful protein, by tissues. Also described are methods of enhancing expression of klotho in cells.

Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of, for example, follistatin, a muscle formation promotion protein, by tissues. Epicardial stimulation is especially useful for heart treatment. Follistatin controlled release is also useful for treating other ailments, such as erectile dysfunction, aortic aneurysm, and failing heart valves.

Abstract: Described is a low voltage, pulsed electrical stimulation device for modulating the expression of sestrin, a useful protein, by tissues. Also described are methods of enhancing expression of sestrins in cells, particularly a method of stimulating the expression and/or release of sestrins in a cell having a gene encoding a sestrin, wherein the method includes applying a bioelectric signal comprising a biphasic constant current at a frequency of, within 15%, 10 Hz to 20 Hz, with a pulse width of, within 15%, 300 to 400 microseconds (?sec).

Abstract: Described is a low voltage, pulsed electrical stimulation device for modulating the expression of NANOG, a useful protein, by cells and tissues. Also described are methods of enhancing expression of NANOG in cells, particularly a method of stimulating the expression and/or release of NANOG in a cell having a gene encoding NANOG, wherein the method includes applying a bioelectric signal of, within 15%, 1 mA to about 5 mA, 20 pulses per second, at 400 microsecond pulse duration to the cell (e.g., directly, indirectly, or wirelessly).

Abstract: Described is a low voltage, pulsed electrical stimulation device for modulating the expression of sirtuin (“SIRT”), a useful protein, by tissues. Also described are methods of enhancing expression of SIRT in cells, particularly a method of stimulating the expression and/or release of SIRT in a cell having a gene encoding SIRT, wherein the method includes applying a bioelectric signal of, within 15%, 50 ?A to about 500 ?A, 20 pps, at 400 ?sec pulse duration to the cell (e.g., directly, indirectly, or wirelessly). In order to downregulate expression of SIRT, the at least one bioelectric signal has a current of at least about 1 mA, as measured at the level of the living cells.

Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of Collagen Type XVII Alpha 1 chain (COL17A1), a useful protein, by tissues. Also described are methods of COL17A1 in cells.

Abstract: Methods of heart valve decalcification may include mechanically removing calcium deposits on a heart valve, and removing debris from the mechanical decalcification via suction. The mechanical removal of the calcium deposits may be accomplished with a burr and/or an ultrasonic device. In some embodiments, mechanical removal of the calcium deposits may be accomplished with a handheld mechanical decalcification device comprising a bur extending from a hand piece. A catheter system for removing plaque deposits from a heart valve may include at least one mechanical decalcification device configured for cleaning the edges of heart valve leaflets, and at least one active aspiration device. The at least one mechanical decalcification device may comprise a bur and/or an ultrasonic device. The system may additionally include a deployable net apparatus configured to encompass at least a portion of a heart valve.

Abstract: A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.

Abstract: Age is an important predictor of neuromuscular recovery after peripheral nerve injury. Insulin-like growth factor 1 (IGF-1) is a potent neurotrophic factor that is known to decline with increasing age. The purpose of this study was to determine if locally delivered IGF-1 would improve nerve regeneration and neuromuscular recovery in aged animals. Young and aged rats underwent nerve transection and repair with either saline or IGF-1 continuously delivered to the site of the nerve repair. After 3 months, nerve regeneration and neuromuscular junction morphology were assessed. In both young and aged animals, IGF-1 significantly improved axon number, diameter, and density. IGF-1 also significantly increased myelination and Schwann cell activity and preserved the morphology of the postsynaptic neuromuscular junction (NMJ), These results show that aged regenerating nerve is sensitive to IGF-1 treatment.

Abstract: Described are a device, system, and method for bioelectric stimulation to accelerate bone integration of an implant and/or bone graft in order to aid healing. Specifically described are devices and methods for enhancing bone integration of a body implant (e.g., a dental implant) or bone graft by modulating (e.g., stimulating) the controlled expression and/or release of selected proteins, which proteins promote osteogenesis and osseointegration via specific bioelectric signals delivered via, e.g., a specialized mouthpiece, electrodes, and/or wireless means. The description particularly relates to the acceleration of the healing of dental implants and/or bone grafts via promoting bone osteointegration more quickly with bioelectric stimulation.

Abstract: Described is a method of treating a subject diagnosed with cancer, breast cancer, bone cancer, lung cancer, osteoporosis, multiple myeloma, and a combination of any thereof by applying a bioelectric signal or signals that upregulate the expression of Osteoprotegerin (“OPG”) and thus beneficially effect the subject's OPG/RANKL/RANK pathway.

Abstract: A minimally invasive circulatory support platform that utilizes an aortic stent pump or pumps is described. The platform uses a low profile catheter-based techniques and provides temporary and chronic circulatory support depending on the needs of the patient. Also described is a catheter-based temporary assist pump to treat patients with acute decompensated heart failure and provide circulatory support to subjects undergoing high risk percutaneous coronary intervention. Further described is a wirelessly powered circulatory assist pump for providing chronic circulatory support for heart failure patients. The platform and system are relatively easy to place, have higher flow rates than existing systems, and provide improvements in the patient's renal function.

Abstract: Described is a low voltage, pulsed electrical stimulation device for modulating (e.g., downregulating) expression of fatty-acid-binding protein 4 (“FABP4”) protein(s) by cellular tissues. In certain embodiments, the device is further programmed or alternatively programmed to produce a bioelectric signal or signals that upregulate expression of, for example, klotho by the tissues.

Abstract: A minimally invasive circulatory support device, system, and related methods. The circulatory assist devices, systems, and methods use low profile catheter-based techniques and provide temporary and chronic circulatory support depending on the needs of the patient. The circulatory assist device, systems, and methods include a stent cage and an impeller. The stent cage is formed of a first material that is sufficiently rigid to expand radially outward and press against an artery wall is sufficiently deformable to collapse within the outer sheath. The impeller includes at least one blade formed of a second material that is sufficiently rigid to expand and retain shape while rotating and assisting blood to flow within the artery and is sufficiently deformable to collapse within the outer sheath with the stent cage.

Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of growth differentiation factor 10 (“GDF10”), a useful protein, by tissues. Also described are methods of enhancing expression of GDF10 in cells, particularly a method of stimulating the expression and/or release of GDF10 in a cell having a gene encoding GDF10, wherein the method includes applying a bioelectric signal produces, as measured at the level of the target cells or tissues being stimulated 2 mA to 4 mA direct current positive to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of cerebral strokes, brain injuries, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's disease, and/or essential tremors are also disclosed.

Abstract: A minimally invasive circulatory support platform that utilizes an aortic stent pump or pumps. The platform uses a low profile catheter-based techniques and provides temporary and chronic circulatory support depending on the needs of the patient. Also described is a catheter-based temporary assist pump to treat patients with acute decompensated heart failure and provide circulatory support to subjects undergoing high risk percutaneous coronary intervention (“PCI”). Further described is a wirelessly powered circulatory assist pump for providing chronic circulatory support for heart failure patients. The platform and system are relatively easy to place, have higher flow rates than existing systems, and provide improvements in the patient's renal function.

Abstract: Described is a low voltage, pulsed electrical stimulation device for controlling expression of Brain-Derived Neurotrophic Factor (“BDNF”), a useful protein, by tissues. Also described are methods of enhancing expression of BDNF in cells, particularly a method of stimulating the expression and/or release of BDNF in a cell having a gene encoding BDNF, wherein the method includes applying a bioelectric signal of from about 10 Hz to about 100 Hz (e.g., 5 Hz, 10 Hz, 40 Hz, 100 Hz, or 110 Hz) to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of Alzheimer's disease, depression, schizophrenia, and post-traumatic stress disorder are also disclosed.

Abstract: Described is precise bioelectrical stimulation of a subject's cellular tissue with a selected bioelectric signal to modulate the expression of a peptide by the cellular tissue. More specifically, the application relates to a device that delivers a programmed bioelectric signal or signals, and associated methods for the controlled modulation of a peptide, such as vascular endothelial growth factor (VEGF) and/or hypoxia-inducible factor 1-alpha (HIF1?), or manipulation of stem cells, via precise bioelectrical signals and sequences useful in, for example, orthodontic and other procedures. The bioelectric signals have preferably been further optimized by selecting a desired pulse width for the peptide(s) to be expressed.

Abstract: Described is a low voltage, pulsed electrical stimulation device for modulating expression of BMP9 protein(s) by cellular tissues.

Abstract: A minimally invasive circulatory support platform that utilizes an aortic stent pump or pumps. The platform uses a low profile catheter-based techniques and provides temporary and chronic circulatory support depending on the needs of the patient. Further described is a wirelessly powered circulatory assist pump for providing chronic circulatory support to, for example, heart failure patients. The platform and system are relatively easy to place, have higher flow rates than existing systems, and provide improvements in the patient's renal function.